Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone844-362-2566
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.10 million
Profitability
Miscellaneous
Employees100
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therapeutics' stock symbol?
Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."
When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?
Shares of Obalon Therapeutics reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Obalon Therapeutics' earnings last quarter?
Obalon Therapeutics Inc (NASDAQ:OBLN) posted its earnings results on Wednesday, July, 24th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.02. The company had revenue of $0.39 million for the quarter, compared to analysts' expectations of $1.82 million. Obalon Therapeutics had a negative return on equity of 253.79% and a negative net margin of 425.36%. View Obalon Therapeutics' Earnings History.
When is Obalon Therapeutics' next earnings date?
What price target have analysts set for OBLN?
4 Wall Street analysts have issued 12 month target prices for Obalon Therapeutics' shares. Their forecasts range from $10.00 to $30.00. On average, they anticipate Obalon Therapeutics' stock price to reach $20.6250 in the next year. This suggests a possible upside of 820.8% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.
What is the consensus analysts' recommendation for Obalon Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.
What are Wall Street analysts saying about Obalon Therapeutics stock?
Here are some recent quotes from research analysts about Obalon Therapeutics stock:
- 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (9/12/2019)
- 2. Northland Securities analysts commented, "We worry that it is only a question of time…… the company commentary this morning was spent on transitioning to the new brick & mortar business model." (7/24/2019)
Has Obalon Therapeutics been receiving favorable news coverage?
Media coverage about OBLN stock has been trending negative on Friday, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Obalon Therapeutics earned a news impact score of -2.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Obalon Therapeutics.
Are investors shorting Obalon Therapeutics?
Obalon Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totalling 39,600 shares, a decline of 88.6% from the July 31st total of 347,800 shares. Based on an average trading volume of 635,900 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.3% of the shares of the company are short sold. View Obalon Therapeutics' Current Options Chain.
Who are some of Obalon Therapeutics' key competitors?
Some companies that are related to Obalon Therapeutics include Invo Bioscience (IVOB), SANUWAVE Health (SNWV), Interpace Diagnostics Group (IDXG), Neovasc (NVCN), PAVmed (PAVM), Restoration Robotics (HAIR), Nuvectra (NVTR), Biostage (BSTG), RA Medical Systems (RMED), Atossa Genetics (ATOS), Co-Diagnostics (CODX), Hancock Jaffe Laboratories (HJLI), DarioHealth (DRIO), Lianluo Smart (LLIT) and Dynatronics (DYNT).
What other stocks do shareholders of Obalon Therapeutics own?
Who are Obalon Therapeutics' key executives?
Obalon Therapeutics' management team includes the folowing people:
- Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
- Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
- Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
- Mr. Mark C. Brister, Chief Technology Officer (Age 57)
- Ms. Daina Schmidt, VP of Marketing
When did Obalon Therapeutics IPO?
(OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.
Who are Obalon Therapeutics' major shareholders?
Obalon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (13.32%), Hoylecohen LLC (5.75%) and Jane Street Group LLC (1.32%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.
Which institutional investors are buying Obalon Therapeutics stock?
OBLN stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Hoylecohen LLC and Jane Street Group LLC. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.
How do I buy shares of Obalon Therapeutics?
Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Obalon Therapeutics' stock price today?
One share of OBLN stock can currently be purchased for approximately $2.24.
How big of a company is Obalon Therapeutics?
Obalon Therapeutics has a market capitalization of $12.48 million and generates $9.10 million in revenue each year. The company earns $-37,380,000.00 in net income (profit) each year or ($19.60) on an earnings per share basis. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.
What is Obalon Therapeutics' official website?
How can I contact Obalon Therapeutics?
Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]
MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
